Business Wire

DEWIZ-GOLF

Share
Jesper Kärrbrink Appointed Chairman of deWiz Golf

deWiz Golf’s Board, including co-founders Christian Bergh and Markus Westerberg, has announced that Jesper Kärrbrink has been appointed new Chairman of the Board. Kärrbrink brings extensive experience from company leadership roles, currently as chairman of Green Jade Games and previously as CEO of, among others, Svenska Spel, Eniro, Euroflorist, Mr. Green, and Östersunds-Posten.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005415/en/

“On behalf of my co-founder Markus and deWiz's board, it is with great pride that I announce that Jesper has been appointed deWiz's new chairman of the board,” said Christian Bergh, co-founder and COO of deWiz Golf. “After five years of development and research, this has been an exciting year with the launch of deWiz and the future is even more exciting with executives like Jesper helping us guide us towards our strategic vision to revolutionize golf and other sports using our world-class wearable technology. Jesper's global experience will be of great value as deWiz expands across golf-rich markets, including North America, Europe and Asia.”

Launched this summer, deWiz is based on revolutionary wearable technology that combines capturing high-precision data of a golfer's swing in real time and biometric feedback to increase a golfer's pace of learning and consistency.

“deWiz is the perfect example of how technology can help players improve their golf game - at all levels,” said Jesper Kärrbrink, new chairman of deWiz Golf. “Artificial intelligence, data collection and motion sensors have been used for a long time to help elite athletes improve their performance. And what's really fascinating about deWiz is how it delivers this high-tech approach at my level, as a dedicated amateur golfer, through a wearable device that helps me to improve my game anywhere, whether I'm on the course, on the range or practicing on my swing at home.”

Today, golfers in the EU, North America and South Korea can buy deWiz and the company plans to expand with new markets in 2022, including Japan, Australia and South Africa.

DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz has been under development for more than five years and has attracted an impressive list of ambassadors, including Bryson DeChambeau, U.S. Open champion from 2020; Annika Sorenstam, 10-time major-champion; Vijay Singh, 3-time major-champion; Lydia Ko, 2-time major champion; 2016 Open-champion Henrik Stenson; 2019 Houston Open-champion Lanto Griffin; and 2-time world champion in long drive, Tim Burke. deWiz's user-friendly app and wearable technology tracks the exact position of a golfer's hands throughout the swing, providing a 3D analysis and delivers data showing Transition , Backswing Length , Wedge Distance and Tempo . These unique deWiz data points provide measurable values ​​that any avid golfer, professional teacher or world-class player can use to effectively refine their swing. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world increase their enjoyment of the game through innovative technology that increases their pace of learning. At the moment, deWiz sells for $699 and is available in the U.S., Canada, Europe and South Korea (more markets are opening regularly - visit the site for the latest updates). Visit dewizgolf.com for more information on how to improve your swing faster or download the app to demonstrate its features via the Apple App Store or Google Play.

Link:

ClickThru

Social Media:

https://www.facebook.com/dewizgolf

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye